IP Library › Granted Patent US 9,487,509
Granted Patent B2
US 9,487,509 · App. 14/055,585 · Granted Nov 8, 2016

Heterocyclic compound

Inventors: Shizuo Kasai (Osaka, JP); Tomohiro Kaku (Osaka, JP); Masahiro Kamaura (Osaka, JP)
Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
C07D417/04C07D205/04C07D207/08C07D207/12C07D211/22C07D211/44C07D211/46C07D211/78C07D211/88C07D401/06C07D401/12C07D403/06C07D403/12C07D413/04C07D413/06C07D413/10C07D413/12C07D417/06C07D417/08C07D417/10C07D471/04C07D495/04C07D513/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,487,509
App. No.
14/055,585
Granted
Nov 8, 2016
Kind
B2
Abstract

The present invention relates to wherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.

Claims (24)

1. A compound represented by the formula

wherein

ring A is benzene optionally further substituted by 1 to 3 substituents selected from the group consisting of (1) a halogen atom, (2) an optionally halogenated C 1-6 alkyl group and (3) an optionally halogenated C 1-6 alkoxy group;

R 1 is an optionally substituted branched C 3-6 alkyl group;

X 1 is O;

X 2 is a C 1-3 alkylene group;

ring B is piperidine;

X 3 is CO; and

R 2 is an acyl group,

or a salt thereof.

2. The compound according to claim 1 , wherein R 1 is an isopropyl group or a tert-butyl group.

3. The compound according to claim 1 , wherein X 2 is methylene.

4. The compound according to claim 1 , wherein ring B is

5. The compound according to claim 1 , wherein ring A is benzene optionally further substituted by 1 to 3 substituents selected from the group consisting of (1) a halogen atom, (2) an optionally halogenated C 1-6 alkyl group and (3) an optionally halogenated C 1-6 alkoxy group;

R 1 is an isopropyl group or a tert-butyl group;

X 1 is O;

X 2 is methylene;

ring B is

X 3 is CO; and

R 2 is an acyl group.

6. {4-[(2-tert-Butyl-4-chlorophenoxy)methyl]piperidin-1-yl}(oxo)acetic acid or a salt thereof.

7. [4-(2-tert-butylphenoxy)piperidin-1-yl](oxo)acetic acid or a salt thereof.

8. {4-[(2-tert-butylphenoxy)methyl]piperidin-1-yl}(oxo)acetic acid or a salt thereof.

9. A pharmaceutical composition comprising the compound according to claim 1 or salt thereof and a pharmacologically acceptable carrier.

Continuity (3)
Division 12738486
Provisional Application 60960897 · Oct 18, 2007
Related Publication 20140066420A1 · Mar 6, 2014